Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income from Continuing Operations (2022 - 2026)

Zentalis Pharmaceuticals has reported Income from Continuing Operations over the past 5 years, most recently at 35352000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 26.78% year-over-year to 35352000.0; the TTM value through Mar 2026 reached 124133000.0, up 44.63%, while the annual FY2025 figure was 137060000.0, 17.37% up from the prior year.
  • Income from Continuing Operations for Q1 2026 was 35352000.0 at Zentalis Pharmaceuticals, roughly flat from 35216000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 10040000.0 in Q1 2024 and troughed at 98860000.0 in Q2 2023.
  • A 5-year average of 49141235.29 and a median of 48279000.0 in 2025 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: surged 116.47% in 2024 and later crashed 580.87% in 2025.
  • Year by year, Income from Continuing Operations stood at 48162000.0 in 2022, then dropped by 26.53% to 60939000.0 in 2023, then rose by 22.1% to 47472000.0 in 2024, then increased by 25.82% to 35216000.0 in 2025, then dropped by 0.39% to 35352000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for ZNTL at 35352000.0 in Q1 2026, 35216000.0 in Q4 2025, and 26691000.0 in Q3 2025.